FDA authorizes Pfizer COVID vaccine booster for ages 5-11
ATLANTA, Georgia — The U.S. Food and Drug Administration has amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine, authorizing the use of a single booster dose for administration to individuals 5 through 11 years of age at least five months after completion of a primary series with the Pfizer-BioNTech COVID-19 Vaccine. […]
FDA authorizes Pfizer COVID vaccine booster for ages 5-11 Read More »